Atlas›Domain XII · Complementary, energy & biofield›Guide 159
Guide XII-159

Caesium chloride high-pH therapy

A. Keith Brewer1984United States
A 29 · L 59 · M 1211 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

Version followed: historical account of caesium (cesium) chloride "high-pH therapy" as described by US regulators (FDA 2018 compounding alert and 2020 supplement alert), Memorial Sloan Kettering's About Herbs monograph (updated 30 June 2022), published case reports, and press reports of a 2010 Western Australian coroner's inquest. This is not a treatment. There is no legitimate implementation for a psychotherapist; this guide exists so clinicians can recognise it, respond to clients drawn to it, and help those harmed.

1. What it was

The substance. Caesium chloride (CsCl) is a non-radioactive salt of the alkali metal caesium. It is not the same as radioactive caesium-137, which is a tightly regulated radiation source in licensed radiotherapy. [source: MSK About Herbs; Nelson, University of Rochester page] It has never been approved by the FDA for cancer or any other use. [source: FDA 2020 public health alert]

Originator and stated rationale. The "high-pH therapy" was promoted in the 1980s by A. Keith Brewer, a physicist with no medical training. In a 1984 paper (Brewer AK, Pharmacology Biochemistry and Behavior, 1984, "The high pH therapy for cancer: tests on mice and humans") he argued, in outline, that:

  • potassium and calcium govern how glucose and oxygen enter cells, and "irritation" of the cell membrane disturbs this, producing the Warburg effect, a fall in cell pH and cancer-like changes;
  • caesium, which resembles potassium chemically, would be taken up by cancer cells, admit oxygen but not glucose, and make the cells alkaline ("high pH") so that they stop dividing and die;
  • populations he named (the Hopi, highland Peruvians, the Hunza) had low cancer rates because of caesium-rich soils. [source: Schwarcz, McGill Office for Science and Society, 2017; MSK About Herbs; reference list of Sessions et al. 2013]

The McGill account notes that Brewer misread Warburg (cancer cells shift metabolism even with oxygen present) and that blood pH is tightly buffered and not changed by caesium or diet. MSK states that "there is no evidence to support use of cesium chloride as a cancer treatment"; a peer-reviewed review concluded that the high-pH hypothesis lacks theoretical and experimental support and that no properly confirmed tumour regression had been reported. [source: McGill; MSK; Melnikov & Zanoni 2010]

The founding "clinical" claim. The main human evidence offered by proponents was a 1984 case series by Hellfried (H. E.) Sartori in the Washington, DC area, published alongside Brewer's paper. FDA reviewers judged it uncontrolled, retrospective and likely affected by selection bias; MSK notes that in this series of people with terminal cancer about a quarter died within two weeks. Brewer's paper credited Sartori with curing over 30 patients; the McGill account says no records of those patients exist. [source: SBM (Bellamy 2018) summarising FDA review; MSK; McGill]

Who used and sold it, where and when.

  • Sartori. Sartori (also known as Abdul-Haqq Sartori, nicknamed "Dr. Ozone") is reported to have served prison sentences in Virginia and New York for defrauding patients with unapproved therapies, to have been arrested in Thailand in 2006 for fraud and practising medicine without a licence, and to have treated patients in Australia (Darwin, Perth, Sydney, South West Rocks) and at a clinic in Thailand. A 2010 Perth coroner's inquest heard that 24 of 25 patients he treated are known to have died; it was not suggested the treatments directly caused the deaths. He admitted exaggerating his treatment's effectiveness and lying to Australian authorities. [source: Canberra Times 2010; McGill 2017]
  • Naturopathic and integrative compounding. In the 2010s the American Association of Naturopathic Physicians nominated caesium chloride for the FDA's list of bulk substances pharmacies may compound, supported by several integrative-medicine organisations and a compounding pharmacy. Nominators described it as "helpful and useful" for numerous cancers in combination with other natural substances and claimed a high remission rate and no observed side effects. FDA reviewers recommended against listing it (2016) and the Pharmacy Compounding Advisory Committee voted 11–0 against. [source: SBM (Bellamy 2018)]
  • Supplements and chemical suppliers. Caesium salts were also sold as dietary supplements and bought from chemical supply houses for self-treatment. [source: FDA 2020; Nelson, University of Rochester page]
  • Wider clinics. Quackwatch reports that a Baltimore businessman treated more than 3,000 patients with an aloe vera and caesium chloride mixture and was sentenced in 2001 to 46 months in federal prison. Contemporaneous news reporting of the case describes intravenous aloe vera courses in the Bahamas and Mexico and does not mention caesium. [source: Quackwatch; HealthDay 2001] [uncertain: caesium component reported by one source only]

How it was sold. As a natural, alkalising, non-toxic alternative to chemotherapy, with marketing calling caesium the "most alkaline nutritional mineral" and practitioners claiming very high cure rates (Sartori claimed 98 per cent, including advanced metastatic cancer). Nominators argued chemotherapy is poorly tolerated and that some patients reasonably choose alternatives. [source: McGill; Canberra Times; SBM]

Regulatory history (US). July 2018: after a citizen petition from Public Citizen and a lawsuit, FDA issued a compounding risk alert on "significant safety risks associated with cesium chloride" and moved it to Category 2 (compounders using it may face warning letters, seizure, injunction or prosecution). February 2020: FDA public health alert telling consumers not to use dietary supplements containing caesium salts because of "heart toxicity and potential death", and telling health professionals not to recommend them. [source: FDA 2020; FDA Law Blog 2018; SBM]

2. What was actually done

A typical course, assembled from regulator and case-report descriptions (administration described qualitatively only):

  1. Selection. People with cancer, very often advanced or metastatic disease, sometimes after or instead of standard treatment; case reports include older adults with breast and colon cancer, a person treated for brain cancer, and an adolescent. [source: MSK reference list; Sessions et al. 2013; Hetavi et al. 2019]
  2. Recruitment and "consent". Patients were offered a cure narrative (alkalise the tumour, starve it of glucose) and told of high cure rates. In the Sartori cases, patients paid large sums (reported as up to US$50,000) and in some cases were insisted to have been cured. No sources describe disclosure of cardiac risk; nominators claimed there were no side effects. [source: McGill; Canberra Times; SBM] [uncertain: consent procedures not documented in sources]
  3. Routes of administration.
    • Oral self-treatment, often over long periods, with products bought as supplements, over the counter, or from chemical suppliers; one case report describes about a year of oral use for a breast mass. [source: Sessions et al. 2013; Hetavi et al. 2019; FDA 2020]
    • Oral use prescribed by a naturopath, in a 2019 case reported to Quackwatch in which a woman had a cardiac arrest after a month of use. [source: Quackwatch]
    • Intravenous infusions in clinics, compounded by pharmacies or practitioners. In Sartori's version, infusions of caesium chloride were combined with magnesium, potassium, vitamins and other chemicals. [source: SBM; Canberra Times]
    • Injection into or around a tumour, in the first reported case of toxicity after attempted intratumoral injection. [source: Sessions et al. 2013]
  4. Bundled components. Sartori's regimen also included coffee enemas, a juice-based diet and ozone treatments; the McGill account also mentions "ozone flushes". [source: Canberra Times; McGill] Other bundles (for example with DMSO or alkaline diets) circulate in proponent literature [uncertain: not verified].
  5. Setting and staff. Unregistered or fraudulent practitioners (Sartori lied about his credentials when applying to register as a doctor in Australia), naturopathic and "integrative" practitioners, compounding pharmacies, home self-treatment, and clinics abroad. [source: Canberra Times; SBM; Quackwatch]
  6. Judging "progress". Progress was asserted by the practitioner (claims of cure) rather than by oncological assessment; Sartori's 1984 "results" had no surviving records. [source: Canberra Times; McGill] Symptoms of toxicity (diarrhoea, nausea, numbness and tingling of the lips) could be present throughout. [source: MSK; Melnikov & Zanoni 2010]
  7. Non-response and refusal. How practitioners handled non-response is not documented in the sources [uncertain: not verified]. Self-treaters were sometimes non-adherent to their prescribed medicines at the same time. [source: Hetavi et al. 2019]

3. How it caused harm

Mechanisms.

  • Potassium disruption. Caesium interferes with potassium channels involved in gut absorption and kidney reabsorption of potassium, causing hypokalaemia and urinary potassium wasting; diarrhoea adds further loss. [source: MSK]
  • Cardiac repolarisation. Caesium affects cardiac ion currents, prolonging the QT interval and producing torsades de pointes, ventricular tachycardia and cardiac arrest; low potassium and slow heart rate amplify the effect. Intravenous caesium caused arrhythmias in dogs. [source: MSK; Hetavi et al. 2019; Melnikov & Zanoni 2010]
  • Neurological. Seizures, syncope, and raised brain caesium with imaging changes have been reported. [source: MSK; FDA 2020]
  • Interactions. Corticosteroids and some diuretics add to potassium loss and may severely lower serum potassium. [source: MSK]
  • Delay of effective treatment. FDA reviewers warned that use could delay patients from receiving effective cancer treatment. [source: SBM summarising FDA review]

Documented harms. By 30 June 2018, FDA had identified 23 reports of harm including six deaths, most often heart-rhythm disturbance. [source: Quackwatch, reporting FDA] FDA lists potentially fatal arrhythmias, hypokalaemia, seizures, syncope and death. [source: FDA 2020]

Case examples (de-identified as published).

  • A woman in her sixties used oral caesium chloride for about a year for a breast mass, then injected it around the mass; about 20 hours later she had a ventricular tachycardia arrest at home, QT over 700 ms after resuscitation, no meaningful neurological recovery, and died within a week. The authors concluded: "There is no demonstrable efficacy, and clear evidence shows life-threatening toxicity." [source: Sessions et al. 2013]
  • A woman in her seventies with stage IV colon cancer, taking over-the-counter caesium as "holistic" treatment and not taking her blood-pressure and diabetes medicines, had a witnessed cardiac arrest with torsades de pointes and marked QT prolongation; she survived after temporary pacing and needed a permanent pacemaker. [source: Hetavi et al. 2019]
  • A woman prescribed caesium chloride by a naturopath had a cardiac arrest after a month and was resuscitated by her husband before hospital care. [source: Quackwatch]
  • Further published reports: long QT and ventricular tachycardia after use for brain cancer; torsades de pointes from a "natural" cancer treatment; QT prolongation in an adolescent; fatal toxicity. [source: MSK reference list]
  • The Perth inquest heard of deaths among Sartori's patients, including a young child with leukaemia. [source: Canberra Times]

Financial and psychological harm. Large out-of-pocket payments (reported up to US$50,000 per patient for Sartori; US$15,000–18,000 per course in the Baltimore case). [source: McGill; HealthDay] Psychological sequelae are not documented in the sources; clinically expect loss of time and quality of remaining life, dashed hope after promised cure, guilt and regret in survivors and bereaved families, and family conflict over the choice [synthesis].

Who was most at risk. People with advanced cancer who feel failed by or fearful of standard treatment; those on diuretics or corticosteroids; those with low potassium or magnesium, slow heart rate or existing heart disease; children given it by adults; self-treaters without medical monitoring. [source: MSK; Hetavi et al. 2019; Canberra Times] [synthesis for the psychological profile]

4. Recognising it today

Names and labels. "High pH therapy", "cesium therapy" or "cesium protocol", "alkaline cancer therapy", caesium or cesium chloride drops, "cesium supplement", "alkaline mineral". MSK lists "High pH therapy" as its common name. [source: MSK; McGill]

Rationales and phrases to listen for. [source: McGill; SBM; Hetavi et al. 2019]

  • "Cancer thrives in acid"; "alkalise the tumour"; "raise your pH".
  • "Caesium starves cancer of sugar" or "lets oxygen in"; misused references to Warburg.
  • "Populations with caesium-rich soil don't get cancer" (Hopi, Hunza, Andean claims).
  • "Most alkaline nutritional mineral"; "natural", "holistic", "non-toxic", "no side effects".
  • "Chemo is poison; this works with your body"; very high cure-rate claims.
  • "It's not radioactive, so it's safe" [synthesis: a plausible reassurance a client may repeat].

Where it or its components still appear.

  • Over-the-counter or online "supplements" despite the FDA alert (FDA noted few such products appeared on the market in 2020). [source: FDA 2020]
  • Purchases from chemical supply houses for self-treatment. [source: Nelson, University of Rochester page]
  • Naturopathic or "integrative" clinics offering compounded injections or infusions; in the US this is now Category 2 for compounding. [source: SBM; FDA Law Blog]
  • Bundles with infusion clinics, coffee enemas, juice diets and ozone, as in the Sartori regimen; clinics abroad. [source: Canberra Times; McGill]
  • Proponent foundations and libraries carrying the founder's name (one such organisation in Wisconsin is described as providing information on caesium treatment). [source: Nelson, University of Rochester page]
  • Wider "alkaline" cancer narratives (alkaline diets, alkaline water) that use the same pH argument; McGill notes that diet changes urine pH, not blood or tumour pH. [source: McGill]

Clinical clues in a client. Palpitations, fainting or near-fainting, seizures, persistent diarrhoea or nausea, numbness or tingling around the lips, and a known QT problem or low potassium on recent tests, in someone with cancer who mentions "alkaline" or "natural" treatment. [source: MSK; Melnikov & Zanoni 2010] Psychological clues: secrecy from the oncology team, sudden cancelling of appointments or treatment, large unexplained spending, and rigid hope in a promised cure [synthesis].

Red flags in a colleague's or service's practice. [synthesis unless cited]

  • Recommending, selling, compounding or referring for caesium, or for any "alkalising" cancer cure.
  • Claims of cure or high remission rates, testimonials instead of records, discouraging standard oncology.
  • Upfront fees for packages, treatment abroad, unverifiable credentials (Sartori lied about his when seeking registration). [source: Canberra Times]
  • Telling clients there are no side effects; no cardiac monitoring; no communication with the treating doctor.
  • A therapist "supporting the protocol" as part of mind–body cancer work.

How legitimate practice differs.

  • Caesium-137 radiotherapy is a regulated radiation source used by licensed oncology teams; it has nothing to do with oral or injected caesium chloride. [source: Nelson, University of Rochester page; MSK]
  • Integrative oncology (see entry 172) uses complementary approaches for symptoms and wellbeing alongside standard treatment, never instead of it, and with the oncology team informed [synthesis; see 172].
  • Laboratory research on tumour acidity is a scientific field and is not evidence for alkaline cures [synthesis].
  • Supportive psychotherapy helps people live with cancer and make decisions; it never endorses or delivers a remedy [synthesis].

5. What to do instead and how to help those harmed

Current alternatives, by name. Standard oncological care from the treating team; early specialist palliative care for symptom control and goals-of-care planning; integrative oncology delivered alongside standard care (entry 172); and psycho-oncology support. Structured psycho-oncology approaches such as Meaning-Centered Psychotherapy, CALM (Managing Cancer and Living Meaningfully) and Dignity Therapy exist for people with advanced cancer [uncertain: not verified]. MSK advises patients to tell their healthcare providers about any herbs, supplements or home remedies they take. [source: MSK patient page] The psychotherapist never supplies, recommends, monitors or "supports" caesium use, and never advises on medicines; medication and supplement questions go to the prescriber or pharmacist [synthesis].

Medical risk at a glance (as clinical sources state it). Caesium chloride can cause potentially fatal arrhythmias, low potassium, seizures, fainting and death; risk rises with diuretics, corticosteroids, low potassium or magnesium and slow heart rate. FDA tells consumers who used it to stop and seek immediate medical care or advice. [source: FDA 2020; MSK; Hetavi et al. 2019]

5.1 Ask routinely, without judgement, and record

  • Purpose: surface caesium or "alkaline" treatments early; many clients do not volunteer them. Use at intake and at every change in cancer status. [synthesis; MSK advises patients to disclose all supplements and remedies]
  • Steps: (1) Normalise: many people try other approaches. (2) Ask open questions about anything taken by mouth, injection or infusion, and about clinics or practitioners seen. (3) Ask by name about "high pH", "alkaline" or caesium products. (4) Record product names, source, who advised it, and whether the treating doctor knows; do not record amounts as advice. [synthesis]
  • Example language (illustrative): "Lots of people with cancer look into other treatments, and I ask everyone. Are you taking or considering anything besides what your oncology team prescribes, such as supplements, drops, infusions, or an alkaline or high-pH approach?"
  • Watch for: guardedness, fear of being judged or reported, and mention of a practitioner who told them not to tell their doctor. Working well: the client discloses and keeps talking about it in later sessions. [synthesis]

5.2 Explore meaning, hopes and the client's explanatory model

  • Purpose: understand what draws the client: control, hope of cure, fear of chemotherapy, distrust of medicine, identity as a "natural" person, a community or practitioner they trust. [synthesis]
  • Steps: (1) Ask how they understand their cancer and how caesium is meant to work. (2) Reflect the underlying values (wanting to live, wanting to avoid suffering, wanting agency). (3) Ask what they were told about results and risks, and what they hope will happen. (4) Separate values (which you affirm) from claims about the product (which belong with their doctor). [synthesis]
  • Example language (illustrative): "It sounds like what matters most is having some control and not being made sicker. Tell me what you were told this treatment would do, and what you are hoping for."
  • Watch for: magical certainty ("it can't fail"), despair underlying the choice, depression or demoralisation, and coercive influence from a seller or group. Working well: the client voices ambivalence or questions they want answered. [synthesis]

5.3 Support informed, values-based decisions (autonomy-respecting)

  • Purpose: help the client make a decision that is genuinely theirs and informed, without coercion. No decision aid specific to caesium is cited here; use generic shared-decision principles [synthesis].
  • Steps: (1) Ask permission before sharing information. (2) Share regulator and cancer-centre facts in plain terms: not approved for any use, FDA warnings of heart toxicity and death, no evidence of benefit (FDA, MSK). (3) Elicit their response. (4) Help them list questions for the oncology team (benefits and burdens of each option, including palliative care). (5) Agree a plan to discuss it with their doctor before any change. (6) Respect a capacitous adult's final choice while keeping the door open. [synthesis; facts from FDA 2020 and MSK]
  • Example language (illustrative): "Would it be OK if I shared what the US regulator and a major cancer centre say about caesium? ... What do you make of that? What questions would you want your oncologist to answer before you decide?"
  • Watch for: arguing (it entrenches the position), the therapist's own alarm overriding the client's pace, and decisions made under a practitioner's time pressure or fee deadline. Working well: the client brings questions to the medical team or agrees to a joint discussion. [synthesis]

5.4 Respond to urgent medical warning signs

  • Purpose: act on symptoms that may signal cardiac or neurological toxicity.
  • Steps: (1) If the client reports fainting, palpitations or a racing or irregular heartbeat, chest pain, seizure, or is unwell in session, treat as an emergency: call emergency services. (2) If they have taken caesium and have milder symptoms (diarrhoea, nausea, lip tingling, dizziness), urge same-day medical review and that they tell the clinician exactly what they took. (3) Do not suggest stopping, continuing or adjusting any product or medicine yourself; route to the doctor. (4) Document. [synthesis; symptom list from MSK, FDA 2020, Melnikov & Zanoni 2010]
  • Example language (illustrative): "Fainting and a pounding heart can be a sign of a dangerous heart rhythm with caesium. I'd like us to call for medical help now, and make sure they know what you've been taking."
  • Watch for: minimising ("it's just detox"), which proponent narratives may encourage [synthesis]. Working well: the client is assessed medically the same day.

5.5 Coordinate with treating physicians, oncology and palliative teams

  • Purpose: close the information gap that makes caesium dangerous (interactions with diuretics and corticosteroids; electrolyte monitoring). [source: MSK]
  • Steps: (1) Seek consent to contact the oncologist, GP or pharmacist. (2) Share only what is needed: the product, route, source, and current symptoms. (3) Offer a joint appointment or help the client prepare to tell the team themselves. (4) Where cancer is advanced, encourage a palliative-care referral via the treating team. (5) Agree who follows up. Without consent, share only where law and your code permit for serious imminent risk. [synthesis]
  • Example language (illustrative): "Your oncologist needs to know about this, because caesium can interact with water tablets and steroids. Would you like to tell them yourself, or would it help if I contacted them with you?"
  • Watch for: fear the team will drop them; reassure that disclosure is about safety. Working well: the medical team is informed and the client stays engaged with both. [synthesis]

5.6 Grief, regret and guilt

  • Purpose: support clients and bereaved relatives after harm, a missed treatment window, or a death following an alternative course. [synthesis]
  • Steps: (1) Let the story be told without judgement. (2) Distinguish responsibility from blame: the person was offered a cure narrative by people who claimed expertise (see section 1). (3) Address counterfactual rumination and self-blame with standard grief and trauma-informed approaches. (4) Screen for prolonged grief, depression and suicidal thinking and follow standard risk assessment. (5) Allow anger at sellers and, where wished, link to reporting (5.10). [synthesis]
  • Example language (illustrative): "You made that choice with the information and the hope you had then, and you were told it would work. It makes sense to feel both grief and anger."
  • Watch for: intrusive images from a resuscitation or sudden death, guilt in the person who supported the choice, and survivors who still believe the treatment worked. Working well: less self-blame and the ability to hold the loss. [synthesis]

5.7 Family conflict

  • Purpose: help families divided over a relative's choice to use caesium or to refuse standard treatment, and after a death. [synthesis]
  • Steps: (1) Meet with the client's consent; clarify whose decision it is (a capacitous adult's). (2) Name the shared aim (wanting the person to live and not suffer). (3) Slow down ultimatums; help relatives voice fear rather than accusations. (4) Help the family agree how to stay connected whatever is chosen, and how to bring questions to the medical team together. (5) After a death, address blame between relatives. [synthesis]
  • Example language (illustrative): "Everyone here wants the same thing, for your mother to have as much good time as possible. Can we hear what each of you is most afraid of?"
  • Watch for: a relative who is also a seller or promoter, estrangement threats, and the ill person withdrawing to avoid conflict. Working well: the family can talk about the decision without rupture. [synthesis]

5.8 Financial harm

  • Purpose: address debt, savings loss and exploitation. Sources report very large fees (up to US$50,000; US$15,000–18,000 per course). [source: McGill; HealthDay]
  • Steps: (1) Ask about costs, crowdfunding or family fundraising, and pressure to pay upfront or to travel abroad. (2) Validate shame. (3) Signpost financial counselling, consumer-protection bodies and legal advice; consider whether fraud reporting applies (5.10). (4) Where an adult at risk is being exploited, follow adult-safeguarding procedures (5.9). [synthesis]
  • Example language (illustrative): "Many people were charged a lot of money for this. Would it help to look at what support exists for getting advice about what you paid?"
  • Watch for: further spending on "top-up" treatments, loans from family, and secrecy. [synthesis]

5.9 Safeguarding

  • Purpose: protect children and adults at risk. Caesium has been given to a child with leukaemia (Perth inquest) and has caused QT prolongation in an adolescent. [source: Canberra Times; MSK reference list]
  • Steps: (1) If a child is being given caesium or another unapproved cancer remedy, or is being kept from medical treatment, treat it as a safeguarding concern: consult your safeguarding lead and the child's medical team and follow local child-protection procedures. (2) For adults lacking capacity or under coercion (by a seller, group or relative), follow adult-safeguarding procedures. (3) Include the young person's own views and assent where appropriate. (4) Document. [synthesis]
  • Example language (illustrative): "Because this involves a child's health and possible harm, I'm required to talk to my safeguarding lead. I'd like to do that together with you where I can."
  • Watch for: parents who believe they are protecting the child; work with their intent while acting on risk. [synthesis]

5.10 Reporting

  • Purpose: report adverse events, illegal sales and unsafe practitioners.
  • Steps: (1) US adverse events from caesium supplements: FDA Safety Reporting Portal; FDA asks health professionals to report patient adverse events there. [source: FDA 2020] (2) Compounded caesium in the US: FDA has said it may act against compounders (warning letters, seizure, injunction, prosecution). [source: SBM; FDA Law Blog] (3) Practitioners: the relevant licensing board (medical, naturopathic, pharmacy). (4) False advertising and fraud: consumer-protection and advertising regulators and police. (5) Outside the US: the national medicines regulator (for example the TGA in Australia, the MHRA in the UK, Health Canada). [uncertain: not verified for (3)–(5)] (6) Deaths may be investigated by a coroner, as in the 2010 Perth inquest. [source: Canberra Times] Obtain consent where confidentiality applies, except where law or imminent risk requires otherwise. [synthesis]
  • Example language (illustrative): "What happened to you can be reported, which may protect others. Would you like help working out how?"
  • Watch for: retaliation fears and group loyalty. Working well: the client chooses whether and how to report. [synthesis]

5.11 The therapist's own ethics and conflicts of interest

  • Steps: Never sell, endorse, refer for or supervise caesium or "alkaline" protocols; do not take referral fees from clinics; work within competence and refer for medical questions; document conversations and consultations. [synthesis; the APA Ethics Code is the reference for US psychologists; specific standards [uncertain: not verified]]
  • Watch for: pressure from clients or colleagues to "just support" the protocol emotionally as part of its delivery. [synthesis]
  • Example language (illustrative): "I can't recommend or help with any cancer remedy, including this one, but I can stay alongside you while you make decisions and help you talk with your medical team."
  • Working well: the client understands your role and keeps both you and the medical team in the loop. [synthesis]

5.12 Handling problems [synthesis throughout]

  • The client will not discuss stopping: stay in relationship; keep focus on safety (warning signs, telling the doctor) rather than winning the argument; revisit at each medical change.
  • Resistance and distrust of medicine: explore the experience behind the distrust; offer to help them find a doctor they can talk to rather than defend any one doctor.
  • Overwhelm: slow down, one question at a time; use grounding; involve palliative care for symptom burden.
  • Rupture after you share risk information: acknowledge it ("I may have come across as dismissing your choice"), restate respect for their autonomy, and repair.
  • Ongoing exposure to a seller or group: explore the relationship, the costs asked, and any pressure to cut contact with family or doctors.
  • Client in medical danger and refusing help: treat as an emergency; follow your service's duty-of-care procedures.
  • Your own distress: use supervision, especially after a client dies.

Sources

← Previous · XII-158Livingston-Wheeler therapyNext · XII-160 →Insulin potentiation therapy